PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that is upregulated on activated T cells for the induction of immune tolerance. Tumour cells frequently overexpress the ligand for PD-1, programmed cell death ligand 1 (PD-L1), facilitating their escape from the immune system. Monoclonal antibodies that block the interaction between PD-1 and PD-L1, by binding to either the ligand or receptor, have shown notable clinical efficacy in patients with a variety of cancers, including melanoma, colorectal cancer, non-small-cell lung cancer and Hodgkin's lymphoma. Although it is well established that PD-1-PD-L1 blockade activates T cells, little is known about the role that this pathway may have in tumour-associated macrophages (TAMs). Here we show that both mouse and human TAMs express PD-1. TAM PD-1 expression increases over time in mouse models of cancer and with increasing disease stage in primary human cancers. TAM PD-1 expression correlates negatively with phagocytic potency against tumour cells, and blockade of PD-1-PD-L1 in vivo increases macrophage phagocytosis, reduces tumour growth and lengthens the survival of mice in mouse models of cancer in a macrophage-dependent fashion. This suggests that PD-1-PD-L1 therapies may also function through a direct effect on macrophages, with substantial implications for the treatment of cancer with these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and treatment with checkpoint inhibitors targeting PD-1 or PD-L1 increases phagocytosis and reduces tumor growth [329].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [329]
In the citing paper
“In human and mouse CRC tumor models, high levels of PD-1 expression on TAM have low tumor phagocytosis”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [329]
In the citing paper
“Tumor-associated macrophages were also recently shown to express PD-1 in both mice and humans with colorectal cancer and to impair macrophage phagocytosis (59).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Cited by
Items 101–200 of 1,001
Hakimi, A. A., Voss, M. H., Kuo, F., Sanchez, A., Liu, M., Nixon, B. G., Vuong, L., Ostrovnaya, I., Chen, Y.-B., Reuter, V., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0957 · Cited by 258
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Xu, Y., Poggio, M., Jin, H. Y., Shi, Z., Forester, C. M., Wang, Y., Stumpf, C. R., Xue, L., Devericks, E., So, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0321-2 · Cited by 261
Therapeutic Targeting of the Macrophage Immune Checkpoint CD47 in Myeloid Malignancies
Chao, M. P., Takimoto, C. H., Feng, D. D., McKenna, K., Gip, P., Liu, J., Volkmer, J.-P., Weissman, I. L., & Majeti, R. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01380 · Cited by 252
Self-citationOncolytic Viruses as Antigen-Agnostic Cancer Vaccines
Russell, S. J., & Barber, G. N. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.011 · Cited by 244
Macrophages and microglia: the cerberus of glioblastoma
Buonfiglioli, A., & Hambardzumyan, D. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01156-z · Cited by 238
Zhao, P., Wang, Y., Kang, X., Wu, A., Yin, W., Tang, Y., Wang, J., Zhang, M., Duan, Y., & Huang, Y. (2018) · Chemical Science · doi:10.1039/c7sc04853j · Cited by 248
Ontogeny of Tumor-Associated Macrophages
Laviron, M., & Boissonnas, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01799 · Cited by 239
Xiang, W., Shi, R., Kang, X., Zhang, X., Chen, P., Zhang, L., Hou, A., Wang, R., Zhao, Y., Zhao, K., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04999-8 · Cited by 243
Cardiotoxicity of immune checkpoint inhibitors
Varricchi, G., Galdiero, M. R., Marone, G., Criscuolo, G., Triassi, M., Bonaduce, D., Marone, G., & Tocchetti, C. G. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000247 · Cited by 246
Wang, S., Li, F., Ye, T., Wang, J., Lyu, C., Qing, S., Ding, Z., Gao, X., Jia, R., Yu, D., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb6981 · Cited by 240
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
Li, Q., Han, J., Yang, Y., & Chen, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1070961 · Cited by 246
“What’s more, recent study has shown that human TAM also expresses PD-1, which increases with the increase of disease stage and show a surface profile similar to M2 (55).”
BackgroundEngineered CAR-Macrophages as Adoptive Immunotherapies for Solid Tumors
Sloas, C., Gill, S., & Klichinsky, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.783305 · Cited by 241
Yin, Y., Liu, B., Cao, Y., Yao, S., Liu, Y., Jin, G., Qin, Y., Chen, Y., Cui, K., Zhou, L., et al. (2022) · Advanced Science · doi:10.1002/advs.202102620 · Cited by 242
Immune checkpoints in the tumor microenvironment
Toor, S. M., Sasidharan Nair, V., Decock, J., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.021 · Cited by 236
Exploiting innate immunity for cancer immunotherapy
Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., & Wu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01885-w · Cited by 225
Hu, G., Guo, M., Xu, J., Wu, F., Fan, J., Huang, Q., Yang, G., Lv, Z., Wang, X., & Jin, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01998 · Cited by 237
Camouflage strategies for therapeutic exosomes evasion from phagocytosis
Parada, N., Romero-Trujillo, A., Georges, N., & Alcayaga-Miranda, F. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.01.001 · Cited by 230
Development of Extracellular Vesicle Therapeutics: Challenges, Considerations, and Opportunities
Claridge, B., Lozano, J., Poh, Q. H., & Greening, D. W. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.734720 · Cited by 227
Dong, L.-Q., Peng, L.-H., Ma, L.-J., Liu, D.-B., Zhang, S., Luo, S.-Z., Rao, J.-H., Zhu, H.-W., Yang, S.-X., Xi, S.-J., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.12.014 · Cited by 232
Tamura, R., Tanaka, T., Akasaki, Y., Murayama, Y., Yoshida, K., & Sasaki, H. (2020) · Medical Oncology · doi:10.1007/s12032-019-1329-2 · Cited by 226
Ge, Z., & Ding, S. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.590941 · Cited by 222
Innate Immunity and Cancer Pathophysiology
Maiorino, L., Daßler-Plenker, J., Sun, L., & Egeblad, M. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-032221-115501 · Cited by 215
Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies
Giraud, J., Chalopin, D., Blanc, J.-F., & Saleh, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.655697 · Cited by 221
Macrophage targeting in cancer
Lopez‐Yrigoyen, M., Cassetta, L., & Pollard, J. W. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14377 · Cited by 221
Tumor-associated myeloid cells: diversity and therapeutic targeting
Mantovani, A., Marchesi, F., Jaillon, S., Garlanda, C., & Allavena, P. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00613-4 · Cited by 219
Current status of immune checkpoint inhibitors for gastric cancer
Kono, K., Nakajima, S., & Mimura, K. (2020) · Gastric Cancer · doi:10.1007/s10120-020-01090-4 · Cited by 220
Lecoultre, M., Dutoit, V., & Walker, P. R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001408 · Cited by 223
Yang, Y., Li, S., To, K. K. W., Zhu, S., Wang, F., & Fu, L. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03377-9 · Cited by 184
Tumor microenvironment in ovarian cancer: function and therapeutic strategy
Yang, Y., Yang, Y., Yang, J., Zhao, X., & Wei, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00758 · Cited by 218
Vassiliou, E., & Farias-Pereira, R. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512032 · Cited by 202
Yang, S., Liu, Q., & Liao, Q. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.607209 · Cited by 203
CAFs Interacting With TAMs in Tumor Microenvironment to Enhance Tumorigenesis and Immune Evasion
Gunaydin, G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668349 · Cited by 202
The tumor microenvironment’s role in the response to immune checkpoint blockade
Aliazis, K., Christofides, A., Shah, R., Yeo, Y. Y., Jiang, S., Charest, A., & Boussiotis, V. A. (2025) · Nature Cancer · doi:10.1038/s43018-025-00986-3 · Cited by 178
Metabolism in tumor microenvironment: Implications for cancer immunotherapy
Shi, R., Tang, Y., & Miao, H. (2020) · MedComm · doi:10.1002/mco2.6 · Cited by 198
Lung Tumor Cell-Derived Exosomes Promote M2 Macrophage Polarization
Pritchard, A., Tousif, S., Wang, Y., Hough, K., Khan, S., Strenkowski, J., Chacko, B. K., Darley-Usmar, V. M., & Deshane, J. S. (2020) · Cells · doi:10.3390/cells9051303 · Cited by 204
The Role of Viral Infections in the Onset of Autoimmune Diseases
Sundaresan, B., Shirafkan, F., Ripperger, K., & Rattay, K. (2023) · Viruses · doi:10.3390/v15030782 · Cited by 184
Emerging concepts in PD-1 checkpoint biology
Pauken, K. E., Torchia, J. A., Chaudhri, A., Sharpe, A. H., & Freeman, G. J. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101480 · Cited by 191
Gastric Cancer: Advances in Carcinogenesis Research and New Therapeutic Strategies
Seeneevassen, L., Bessède, E., Mégraud, F., Lehours, P., Dubus, P., & Varon, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073418 · Cited by 185
MIF-Dependent Control of Tumor Immunity
Noe, J. T., & Mitchell, R. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.609948 · Cited by 198
Lipid-loaded tumor-associated macrophages sustain tumor growth and invasiveness in prostate cancer
Masetti, M., Carriero, R., Portale, F., Marelli, G., Morina, N., Pandini, M., Iovino, M., Partini, B., Erreni, M., Ponzetta, A., et al. (2022) · Journal of Experimental Medicine · doi:10.1084/jem.20210564 · Cited by 189
Self-citationTumor Infiltrating Lymphocyte (TIL) Therapy for Solid Tumor Treatment: Progressions and Challenges
Zhao, Y., Deng, J., Rao, S., Guo, S., Shen, J., Du, F., Wu, X., Chen, Y., Li, M., Chen, M., et al. (2022) · Cancers · doi:10.3390/cancers14174160 · Cited by 197
Saito, Y., Chikenji, T. S., Matsumura, T., Nakano, M., & Fujimiya, M. (2020) · Nature Communications · doi:10.1038/s41467-020-14734-x · Cited by 196
M1 Macrophages Induce PD-L1 Expression in Hepatocellular Carcinoma Cells Through IL-1β Signaling
Zong, Z., Zou, J., Mao, R., Ma, C., Li, N., Wang, J., Wang, X., Zhou, H., Zhang, L., & Shi, Y. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01643 · Cited by 196
Tumor-Associated-Macrophage-Membrane-Coated Nanoparticles for Improved Photodynamic Immunotherapy
Chen, C., Song, M., Du, Y., Yu, Y., Li, C., Han, Y., Yan, F., Shi, Z., & Feng, S. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c00818 · Cited by 193
Wei, J., Chen, P., Gupta, P., Ott, M., Zamler, D., Kassab, C., Bhat, K. P., Curran, M. A., de Groot, J. F., & Heimberger, A. B. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz212 · Cited by 191
Dhupkar, P., Gordon, N., Stewart, J., & Kleinerman, E. S. (2018) · Cancer Medicine · doi:10.1002/cam4.1518 · Cited by 183
Sedighzadeh, S. S., Khoshbin, A. P., Razi, S., Keshavarz-Fathi, M., & Rezaei, N. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-1241 · Cited by 189
Spatially Segregated Macrophage Populations Predict Distinct Outcomes in Colon Cancer
Matusiak, M., Hickey, J. W., van IJzendoorn, D. G. P., Lu, G., Kidziński, L., Zhu, S., Colburg, D. R. C., Luca, B., Phillips, D. J., Brubaker, S. W., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-1300 · Cited by 168
Zhao, Y., Harrison, D. L., Song, Y., Ji, J., Huang, J., & Hui, E. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.054 · Cited by 188
Hsieh, R. C.-E., Krishnan, S., Wu, R.-C., Boda, A. R., Liu, A., Winkler, M., Hsu, W.-H., Lin, S. H., Hung, M.-C., Chan, L.-C., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abl9330 · Cited by 182
WNT signaling and cancer stemness
Katoh, M., & Katoh, M. (2022) · Essays in Biochemistry · doi:10.1042/ebc20220016 · Cited by 179
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Qiao, M., Jiang, T., Liu, X., Mao, S., Zhou, F., Li, X., Zhao, C., Chen, X., Su, C., Ren, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.003 · Cited by 186
Insights from a 30-year journey: function, regulation and therapeutic modulation of PD1
Chamoto, K., Yaguchi, T., Tajima, M., & Honjo, T. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-023-00867-9 · Cited by 185
“Not only lymphoid cells but also myeloid cells such as macrophages and DCs express PD1, which has been shown to induce immune tolerance in tumours and infection settings 110,111 .”
BackgroundImmune checkpoint inhibitors: Key trials and an emerging role in breast cancer
Gaynor, N., Crown, J., & Collins, D. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.016 · Cited by 182
Tumor-Associated Macrophage Status in Cancer Treatment
Malfitano, A. M., Pisanti, S., Napolitano, F., Di Somma, S., Martinelli, R., & Portella, G. (2020) · Cancers · doi:10.3390/cancers12071987 · Cited by 184
The role of efferocytosis‐fueled macrophage metabolism in the resolution of inflammation
Schilperoort, M., Ngai, D., Sukka, S. R., Avrampou, K., Shi, H., & Tabas, I. (2023) · Immunological Reviews · doi:10.1111/imr.13214 · Cited by 170
Obesity induces PD-1 on macrophages to suppress anti-tumour immunity
Bader, J. E., Wolf, M. M., Lupica-Tondo, G. L., Madden, M. Z., Reinfeld, B. I., Arner, E. N., Hathaway, E. S., Steiner, K. K., Needle, G. A., Hatem, Z., et al. (2024) · Nature · doi:10.1038/s41586-024-07529-3 · Cited by 167
Benner, B., Scarberry, L., Suarez-Kelly, L. P., Duggan, M. C., Campbell, A. R., Smith, E., Lapurga, G., Jiang, K., Butchar, J. P., Tridandapani, S., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0622-0 · Cited by 183
“Given the hypothesis that TAM regulate T cell suppression through the expression of PD-L1 we evaluated the ability of in vitro generated TAM to suppress T cell proliferation [23, 24].”
BackgroundRadiotherapy–immunotherapy combinations – perspectives and challenges
Mondini, M., Levy, A., Meziani, L., Milliat, F., & Deutsch, E. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12658 · Cited by 174
Han, X., Wei, Q., Lv, Y., Weng, L., Huang, H., Wei, Q., Li, M., Mao, Y., Hua, D., Cai, X., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2021.08.028 · Cited by 170
Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives
Yshii, L. M., Hohlfeld, R., & Liblau, R. S. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.144 · Cited by 173
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies
Zhu, S., Yi, M., Wu, Y., Dong, B., & Wu, K. (2021) · Experimental Hematology & Oncology · doi:10.1186/s40164-021-00252-z · Cited by 178
Dodagatta-Marri, E., Meyer, D. S., Reeves, M. Q., Paniagua, R., To, M. D., Binnewies, M., Broz, M. L., Mori, H., Wu, D., Adoumie, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0493-9 · Cited by 177
“The third cluster of predominantly non-responding tumors, Cluster C, was characterized by lower levels of CD8+ cells and Ly6Chi TAMs, but higher levels of CTLA4 +Tregs, Ly6Clo TAMs and a high Ly6Clo/Ly6Chi TAM ratio, compared to responding Clusters A and B (Fig.”
BackgroundInfluentialRadiotherapy in combination with CD47 blockade elicits a macrophage-mediated abscopal effect
Nishiga, Y., Drainas, A. P., Baron, M., Bhattacharya, D., Barkal, A. A., Ahrari, Y., Mancusi, R., Ross, J. B., Takahashi, N., Thomas, A., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00456-0 · Cited by 176
Self-citationTargeting of TAMs: can we be more clever than cancer cells?
Kzhyshkowska, J. G., Shen, J., & Larionova, I. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01232-z · Cited by 201
Meder, L., Schuldt, P., Thelen, M., Schmitt, A., Dietlein, F., Klein, S., Borchmann, S., Wennhold, K., Vlasic, I., Oberbeck, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2176 · Cited by 170
Lee, J. B., Kim, H. R., & Ha, S.-J. (2022) · Immune Network · doi:10.4110/in.2022.22.e2 · Cited by 174
Targeting macrophages in hematological malignancies: recent advances and future directions
Li, W., Wang, F., Guo, R., Bian, Z., & Song, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01328-x · Cited by 167
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 162
Bader, J. E., Enos, R. T., Velázquez, K. T., Carson, M. S., Nagarkatti, M., Nagarkatti, P. S., Chatzistamou, I., Davis, J. M., Carson, J. A., Robinson, C. M., et al. (2018) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00229.2017 · Cited by 168
de Groot, J., Penas-Prado, M., Alfaro-Munoz, K., Hunter, K., Pei, B. L., O’Brien, B., Weathers, S.-P., Loghin, M., Kamiya Matsouka, C., Yung, W. K. A., et al. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noz185 · Cited by 170
High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model
Luchtel, R. A., Bhagat, T., Pradhan, K., Jacobs, W. R., Levine, M., Verma, A., & Shenoy, N. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1908158117 · Cited by 167
Heparanase and the hallmarks of cancer
Jayatilleke, K. M., & Hulett, M. D. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02624-1 · Cited by 181
Heterogeneity of response to immune checkpoint blockade in hypermutated experimental gliomas
Aslan, K., Turco, V., Blobner, J., Sonner, J. K., Liuzzi, A. R., Núñez, N. G., De Feo, D., Kickingereder, P., Fischer, M., Green, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14642-0 · Cited by 162
Monocyte-derived macrophages promote breast cancer bone metastasis outgrowth
Ma, R.-Y., Zhang, H., Li, X.-F., Zhang, C.-B., Selli, C., Tagliavini, G., Lam, A. D., Prost, S., Sims, A. H., Hu, H.-Y., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20191820 · Cited by 162
The Role of Antigen Spreading in the Efficacy of Immunotherapies
Brossart, P. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0305 · Cited by 180
Re-Education of Macrophages as a Therapeutic Strategy in Cancer
Kowal, J., Kornete, M., & Joyce, J. A. (2019) · Immunotherapy · doi:10.2217/imt-2018-0156 · Cited by 161
Immune escape: A critical hallmark in solid tumors
Mortezaee, K. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118110 · Cited by 158
Li, W., Wu, F., Zhao, S., Shi, P., Wang, S., & Cui, D. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.07.004 · Cited by 158
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy
Jiang, W., Pan, S., Chen, X., Wang, Z. P., & Zhu, X. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01406-7 · Cited by 174
Modulating inflammation for cancer therapy
Ritter, B., & Greten, F. R. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181739 · Cited by 159
Programmed cell removal by calreticulin in tissue homeostasis and cancer
Feng, M., Marjon, K. D., Zhu, F., Weissman-Tsukamoto, R., Levett, A., Sullivan, K., Kao, K. S., Markovic, M., Bump, P. A., Jackson, H. M., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05211-7 · Cited by 156
Self-citationCD47–SIRPα-targeted therapeutics: status and prospects
Maute, R. L., Xu, J., & Weissman, I. L. (2022) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2022.100070 · Cited by 195
Self-citationZhang, Y.-L., Li, Q., Yang, X.-M., Fang, F., Li, J., Wang, Y.-H., Yang, Q., Zhu, L., Nie, H.-Z., Zhang, X.-L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2867 · Cited by 160
Yang, L., & Lin, P. C. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.001 · Cited by 155
Zhao, L., Shi, W., Hu, F., Song, X., Cheng, Z., & Zhou, J. (2021) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2021.112882 · Cited by 168
Lu, C., Liu, Y., Ali, N. M., Zhang, B., & Cui, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1039260 · Cited by 182
Activation of JUN in fibroblasts promotes pro-fibrotic programme and modulates protective immunity
Cui, L., Chen, S.-Y., Lerbs, T., Lee, J.-W., Domizi, P., Gordon, S., Kim, Y.-H., Nolan, G., Betancur, P., & Wernig, G. (2020) · Nature Communications · doi:10.1038/s41467-020-16466-4 · Cited by 153
Self-citationMorgan, M. A., Büning, H., Sauer, M. G., & Schambach, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01965 · Cited by 157
Chang (2018) · doi:10.3389/fmicb.2018.00983 · Cited by 152
Bailey, C. M., Liu, Y., Liu, M., Du, X., Devenport, M., Zheng, P., Liu, Y., & Wang, Y. (2022) · Journal of Clinical Investigation · doi:10.1172/jci150846 · Cited by 151
Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy
Falcone, I., Conciatori, F., Bazzichetto, C., Ferretti, G., Cognetti, F., Ciuffreda, L., & Milella, M. (2020) · Cancers · doi:10.3390/cancers12102870 · Cited by 170
Zheng, Y., Han, Y., Sun, Q., & Li, Z. (2022) · Exploration · doi:10.1002/exp.20210166 · Cited by 169
CD47/SIRPα axis: bridging innate and adaptive immunity
van Duijn, A. V. D. P. , van der Burg, S. H., & Scheeren, F. A. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004589 · Cited by 164
Cancer-Associated Fibroblasts and Tumor-Associated Macrophages in Cancer and Cancer Immunotherapy
Raskov, H., Orhan, A., Gaggar, S., & Gögenur, I. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.668731 · Cited by 150
“Thus, TAM expressing immune checkpoint receptor ligands limit the functions of effector T cells, NK cells, and dendritic cells, and attenuate the effects of immune checkpoint inhibitor therapy (101, 102).”
BackgroundWang, F., Li, B., Wei, Y., Zhao, Y., Wang, L., Zhang, P., Yang, J., He, W., Chen, H., Jiao, Z., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0049-3 · Cited by 157
Dual Role of Macrophage in Tumor Immunity
Tamura, R., Tanaka, T., Yamamoto, Y., Akasaki, Y., & Sasaki, H. (2018) · Immunotherapy · doi:10.2217/imt-2018-0006 · Cited by 145
Chen, C., Guo, Q., Liu, Y., Hou, Q., Liao, M., Guo, Y., Zang, Y., Wang, F., Liu, H., Luan, X., et al. (2023) · Clinical and Translational Medicine · doi:10.1002/ctm2.1515 · Cited by 167
Yin, T., Fan, Q., Hu, F., Ma, X., Yin, Y., Wang, B., Kuang, L., Hu, X., Xu, B., & Wang, Y. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c01863 · Cited by 147
Metadata
- Authors
- Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., Ring, A. M., Connolly, A. J., & Weissman, I. L.
- Affiliations
- Stanford Medicine (US)
- Institute for Stem Cell Biology and Regenerative Medicine (US)
- Yale University (US)
- Corresponding author
- Weissman, Irving L.
- ORCID
- Venue
- Nature
- Published
- 2017-05
- Volume
- 545
- Issue
- 7655
- Pages
- 495-499
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5931375
- OpenAlex
- W2615301036
- Cited by
- 2,247
- References
- 34
- Citations by year
- 2026: 167 · 2025: 261 · 2024: 303 · 2023: 298 · 2022: 309 · 2021: 299 · 2020: 264 · 2019: 158 · 2018: 135 · 2017: 51
- FWCI
- 75.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Science Foundation
- Cancer Research Institute
- A.P. Giannini Foundation
- Giannini Foundation of Agricultural Economics
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (155336)
- National Institutes of Health (1s10rr026780-01)
- National Cancer Institute (R01CA086017, P30CA124435)
- National Institute of General Medical Sciences (T32GM007365)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32AR050942)
- National Center for Research Resources (1S10RR02678001, 1S10RR026780, S10 RR026780)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- PD-1, tumour-associated macrophages, PD-L1, phagocytosis, immune checkpoint blockade, tumour immunity, cancer immunotherapy, tumour-infiltrating macrophages
- MeSH terms
- Animals, Colonic Neoplasms, Disease Models, Animal, Female, Humans, Macrophages, Male, Mice, Inbred BALB C, Neoplasm Staging, Phagocytosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.